Ambulatory Ritonavir-Boosted Nirmatrelvir and Molnupiravir Associated with Reduced Hospitalization and Death
Discover more from Courageous Discourse™ with Dr. Peter McCullough & John Leake
Ambulatory Ritonavir-Boosted Nirmatrelvir and Molnupiravir Associated with Reduced Hospitalization and Death
More than Half of Hospitalizations and Deaths were Vaccine Boosted Cleveland Clinic Patients
By Peter A. McCullough, MD, MPH
Ritonavir-boosted nirmatrelvir and molnupiravir are currently used in the US and in other countries as part of the McCullough Protocol to treat nonhospitalized patients who have mild-to-moderate COVID-19 and who are at high risk for progression to severe disease. Lin et al from the Cleveland Clinic reported on these two oral antiviral drugs with respect to hospitalization and death resulting from infection with new SARS-CoV-2 Omicron subvariants, particularly BQ.1.1 and XBB.1.5.
Because both drugs are a proxy for early multidrug intervention and a better standard of care than nothing, they were associated with substantial reductions in hospitalization and death as ivermectin and hydroxychloroquine have been demonstrated in similar prior non-randomized studies.
It was interesting to note that more than half of the hospitalizations and deaths occurred in fully vaccinated and boosted Cleveland Clinic patients.
The bottom line is that early multidrug therapy remains the community standard of care for high-risk COVID-19 and only those who receive no treatment are at risk for hospitalization and deaths. Vaccination has no impact on these serious outcomes.
Subscribe to Courageous Discourse as a paying or founder member so we can continue to bring you the truth at a time when you need it the most.
Peter A. McCullough, MD, MPH
President, McCullough Foundation
Ambulatory Ritonavir-Boosted Nirmatrelvir and Molnupiravir Associated with Reduced Hospitalization and Death
Given the track record of Ivermectin and Hydroxychloroquine, what is the justification for using these extremely expensive agents that are new, without long term safety studies, when IVM and HCQ are affordable and have proved efficacy and safety for years?
Am I missing something here? Maybe this is going over my head.
I looked only at the chart displayed; did not go and read the paper. My concern is that using ANY drug recommended by the "regime" during the fake pandemic, while the government and our entire healthcare system coerced patients to take malnu. . . retin. . . whatever(!), is for the adverse events yet to show up-- not documented in this paper.
What about the potential for liver damage and other compromised function as a result of taking these? Is this being ignored? Including these drugs in Dr McCullough's protocol ,alone, is concerning. I would like to hear more. . .
At least, in the protocol offered here, Dr McCullough lists these drugs on the same level as HCQ & IVM combos. possibly offering priority levels for these three would be a good addition.